Most engineered ACT targets in HCC fall into three categories: tumor-associated or tumor-specific antigens (AFP, GPC-3), viral-derived antigens (HBV, HCV), and cancer-testis antigens (NY-ESO-1, MAGE). This evidence concerns the gene GPC3 and neoplasm.